Literature DB >> 21484591

When there's smoke there's…scleroderma: evidence that patients with scleroderma should stop smoking.

Andrew Leask1.   

Abstract

There is no treatment for the autoimmune disease scleroderma (systemic sclerosis, SSc), a multisystem disorder characterized by vascular damage and fibrosis. In particular, SSc can severely affect the lung, resulting in pulmonary arterial hypertension and fibrosis. Smoking is well-known to affect pulmonary health, and a recent report (Hudson et al., Arthritis Rheum, in press Oct 8) provides convincing evidence that stopping smoking improves disease outcome in SSc patients. This commentary discusses this recent publication which suggests that physicians should encourage SSc patients to stop smoking immediately.

Entities:  

Year:  2011        PMID: 21484591      PMCID: PMC3058191          DOI: 10.1007/s12079-010-0111-1

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  9 in total

Review 1.  Evidence-based management of rapidly progressing systemic sclerosis.

Authors:  Dinesh Khanna; Christopher P Denton
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-06       Impact factor: 4.098

Review 2.  The 'healthy smoker': a phenomenon of health selection?

Authors:  M R Becklake; U Lalloo
Journal:  Respiration       Date:  1990       Impact factor: 3.580

3.  Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study.

Authors:  G I Greenwald; D P Tashkin; H Gong; M Simmons; S Duann; D E Furst; P Clements
Journal:  Am J Med       Date:  1987-07       Impact factor: 4.965

4.  Cigarette smoking in patients with systemic sclerosis.

Authors:  Marie Hudson; Ernest Lo; Ying Lu; Daniel Hercz; Murray Baron; Russell Steele
Journal:  Arthritis Rheum       Date:  2011-01

5.  When there's smoke there's.....CCN2.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2010-08-17       Impact factor: 5.782

6.  Deterioration of lung function is associated with presence of IgM rheumatoid factor and smoking in patients with systemic sclerosis.

Authors:  Berit Broholm; Susanne Ullman; Poul Halberg; Søren Jacobsen
Journal:  Clin Rheumatol       Date:  2008-06-05       Impact factor: 2.980

Review 7.  Tobacco smoke-related diffuse lung diseases.

Authors:  Robert Vassallo; Jay H Ryu
Journal:  Semin Respir Crit Care Med       Date:  2009-02-16       Impact factor: 3.119

8.  Patterns of pulmonary function in smoking and nonsmoking patients with progressive systemic sclerosis.

Authors:  Silvia A Quadrelli; Luciana Molinari; Lorena M Ciallella; Martin Bosio; Alejandro Salvado
Journal:  Rheumatol Int       Date:  2009-01-08       Impact factor: 2.631

Review 9.  Coronary microvascular dysfunction.

Authors:  Paolo G Camici; Filippo Crea
Journal:  N Engl J Med       Date:  2007-02-22       Impact factor: 91.245

  9 in total
  2 in total

1.  Deregulated angiogenesis in chronic lung diseases: a possible role for lung mesenchymal progenitor cells (2017 Grover Conference Series).

Authors:  Jonathan A Kropski; Bradley W Richmond; Christa F Gaskill; Robert F Foronjy; Susan M Majka
Journal:  Pulm Circ       Date:  2017-10-17       Impact factor: 3.017

2.  Prevalence of pulmonary hypertension in patients with systemic sclerosis and mixed connective tissue disease.

Authors:  Karolina Niklas; Arkadiusz Niklas; Tatiana Mularek-Kubzdela; Mariusz Puszczewicz
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.